Teclistamab in relapsed and refractory multiple myeloma: patients characteristics from post marketing acces (acces precoce) in France

被引：0
|
作者：
Harel, Stephanie [1 ]
de Colella, Jean-Marc Schiano [2 ]
Sonntag, Cecile [3 ]
Cazaubiel, Titouan [4 ]
Garderet, Laurent [5 ]
Bouillie, Sylvie [6 ]
Javelot, Matthieu [7 ]
Vernet, Sophie [7 ]
Perrot, Aurore [8 ]
机构：
[1] St Louis Hosp, Immunohematol Dept, AP HP, Paris, France
[2] AMU, Inst Paoli Calmettes, CRCM, Marseille, France
[3] ICANS, Dept Hematol, Strasbourg, France
[4] CHU Bordeaux, Bordeaux, France
[5] Hop St Antoine, Serv Hematol & Therapie Cellulaire, AP HP, Paris, France
[6] Janssen Cilag France, Issy Les Moulineaux, France
[7] Med Affair Janssen Cilag France, Issy Les Moulineaux, France
[8] Inst Univ Canc Toulouse Oncopole, Toulouse, France
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-014
引用
收藏
页码：S40 / S41
页数：2
相关论文
共 50 条
  • [41] Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance
    Kakimoto, Yoshihide
    Hoshino, Miyako
    Hashimoto, Mikiko
    Hiraizumi, Masaya
    Shimizu, Kohei
    Chou, Takaaki
    INTERNAL MEDICINE, 2022, 61 (09) : 1337 - 1343
  • [42] Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial
    Matous, Jeffrey, V
    van de Donk, Niels W. C. J.
    Oriol, Albert
    Garfall, Alfred L.
    Rodriguez-Otero, Paula
    Chalopin, Thomas
    Dachs, Laura Rosinol
    Uttervall, Katarina
    Mateos, Maria- Victoria
    Trancucci, Danielle
    Carde, Natalia Quijano
    Hodin, Caroline
    Stephenson, Tara
    Zuppa, Athena
    Chastain, Katherine
    Karlin, Lionel
    BLOOD, 2024, 144 : 4749 - 4750
  • [43] Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study
    Rodriguez-Otero, Paula
    Dholaria, Bhagirathbhai
    Askari, Elham
    Reece, Donna E.
    van de Donk, Niels W. C. J.
    Chari, Ajai
    Goldschmidt, Hartmut
    Krishnan, Amrita Y.
    Martin, Thomas
    Mateos, Maria-Victoria
    Giles, Daniel Morillo
    Rodriguez, Cesar
    Rosinol, Laura
    San-Miguel, Jesus F.
    Sureda, Anna
    Waesch, Ralph
    Weisel, Katja
    Verona, Raluca I.
    Lin, Shun Xin Wang
    Prior, Thomas J.
    Weiss, Brendan M.
    Wade, Mark
    Goldberg, Jenna D.
    Oriol, Albert
    Hari, Parameswaran
    BLOOD, 2021, 138
  • [44] Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest
    Stepanovic, Adam
    Abonour, Rafat
    Abu Zaid, Mohammad
    Farag, Sherif
    Lee, Kelvin P.
    Suvannasankha, Attaya
    BLOOD, 2023, 142
  • [45] Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naive in Relapsed/Refractory Multiple Myeloma
    Snyder, Jordan
    Graf, Kevin
    Davis, James A.
    Mckenna, Marshall
    Tiger, Yun Kyoung
    Laharwal, Mehak M.
    Mewawalla, Prerna
    Alkharabsheh, Omar
    Hashmi, Hamza
    Shaikh, Hira
    Lochner, Jonathan
    Chang, Darryl
    Atrash, Shebli
    Habib, Alma
    Venkatesh, Priyanka
    Mahmoudjafari, Zahra
    Ahmed, Nausheen
    Mushtaq, Muhammad Umair
    Abdallah, Al-Ola
    Green, Kimberly M.
    Khan, Abdullah Mohammad
    BLOOD, 2024, 144 : 24117 - 24118
  • [46] French Monocentric Experience of Outpatient Step-up Dosing of Teclistamab in Relapsed Refractory Multiple Myeloma
    Hebraud, Benjamin
    Granell, Miguel
    Lapierre, Leopoldine
    Mouchel, Pierre Luc
    Beziat, Guillaume
    Sicard, Nina
    Bonneau, Maeva
    Higue, Jules
    Sougy, Florence
    Perriat, Sophie
    Morel, Charlotte
    Bories, Pierre
    Corre, Jill
    Loiseau, Herve Avet
    Recher, Christian
    Perrot, Aurore
    BLOOD, 2023, 142
  • [47] Characterization of Anthropometric Changes in Patients with Relapsed/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab
    Nader, Setarah Mohammad
    Jines, Tyler
    Collier, Christopher
    Zimmers, Teresa
    Abonour, Rafat
    Farag, Sherif
    Abu Zaid, Mohammad
    Lee, Kelvin P.
    Suvannasankha, Attaya
    BLOOD, 2023, 142
  • [48] Safety and efficacy of standard of care (SOC) teclistamab (TEC) in patients with relapsed/refractory multiple myeloma (RRMM), a single center experience
    Grajales-Cruz, Ariel
    Khadka, Sushmita
    Blue, Brandon
    Hansen, Doris
    Puglianini, Omar Castaneda
    Freeman, Ciara
    De Avila, Gabriel
    Ochoa-Bayona, Leonel
    Liu, Hien
    Nishihori, Taiga
    Locke, Frederick
    Shain, Ken
    Baz, Rachid
    Alsina, Melissa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S39 - S40
  • [49] Initial report of a single institution experience with teclistamab for relapsed or refractory multiple myeloma including prior BCMA
    Faiman, Beth
    Dima, Danai
    Duco, Marissa
    Rice, Mikhaila
    Rudoni, Joslyn
    Anwer, Faiz
    Khouri, Jack
    Mazzoni, Sandra
    Raza, Shahzad
    Samaras, Christy
    Williams, Louis
    Valent, Jason
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S177 - S177
  • [50] Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study
    Cortes-Selva, Diana
    Perova, Tatiana
    Skerget, Sheri
    Vishwamitra, Deeksha
    Stein, Sarah
    Boominathan, Rengasamy
    Lau, Onsay
    Calara-Nielsen, Karl
    Davis, Cuc
    Patel, Jaymala
    Banerjee, Arnob
    Stephenson, Tara
    Uhlar, Clarissa
    Kobos, Rachel
    Goldberg, Jenna
    Pei, Lixia
    Trancucci, Danielle
    Girgis, Suzette
    Lin, Shun Xin Wang
    Wu, Liviawati S.
    Moreau, Philippe
    Usmani, Saad Z.
    Bahlis, Nizar J.
    van de Donk, Niels W. C. J.
    Verona, Raluca I.
    BLOOD, 2024, 144 (06) : 615 - 628
12345